News|Articles|November 1, 2006

Pipeline Preview (November 2006)

Lisdexamfetamine (NRP104, Shire/New River Pharmaceuticals) for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)

Approvable designations

Fast-track designations

Orphan drug designations


Related to this article

8 takeaways from the MHE and Drug Topics post-midterms webinar
Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.